Economic evaluation of ivabradine in the treatment of XXXX in Greece.

@entity1 @entity712
BACKGROUND: The objective of our study was to assess the cost-effectiveness of ivabradine plus standard care (SoC) in @entity712 ( @entity712 ) @entity1 with sinus rhythm and a baseline heart rate   >=    75 b.p.m. in Greece, in comparison with current SoC alone. METHODS: An existing cost-effectiveness model consisting of two health states, was adapted to the Greek health care setting. All clinical inputs of the model (i.e. mortality rates, hospitalization rates, NYHA class distribution and utility values) were estimated from SHIFT trial data. All costing data used in the model reflects the year 2013 (in    ). An incremental cost effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained was calculated. Deterministic and probabilistic sensitivity analyses (PSA) were conducted. The horizon of analysis was over @entity1 life time and both cost and outcomes were discounted at 3.5% per year. The analysis was conducted from a Greek third party-payer perspective. RESULTS: The Markov analysis revealed that the discounted quality-adjusted survival was 4.27 and 3.99 QALYs in the ivabradine plus SoC and SoC alone treatment arms, respectively. The cumulative lifetime total cost per @entity1 was    8,665 and    5,873, for ivabradine plus SoC and SoC alone, respectively. The ICER for ivabradine plus SoC versus SoC alone was estimated as    9,986 per QALY gained. The PSA showed that the likelihood of ivabradine plus SoC being cost-effective at a threshold of    36,000/QALY was found to be 95%. CONCLUSIONS: Ivabradine plus SoC may be regarded as a  cost-effective option for the treatment in @entity712 @entity1 in Greece.
